Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Harvard Medical School
Information provided by (Responsible Party):
David Avigan, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00622401
First received: February 14, 2008
Last updated: September 15, 2014
Last verified: September 2014
  Purpose

The purpose of this study is to test the safety of an investigational Dendritic Cell/Tumor Fusion vaccine given with IL-12 for patients with breast cancer.

RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Interleukin-12 may stimulate the white blood cells to kill tumor cells. Giving vaccine therapy together with interleukin-12 may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of interleukin-12 when given together with vaccine therapy and to see how well they work in treating women with stage IV breast cancer.


Condition Intervention Phase
Breast Cancer
Biological: Dendritic Cell/Tumor Fusion Vaccine
Drug: Interleukin-12
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12

Resource links provided by NLM:


Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • To assess the toxicity associated with vaccination of breast cancer patients with dendritic cell(DC)/tumor fusions and rhIl-12. [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To determine if cellular and humoral immunity is induced by serial vaccination with DC/tumor fusion cells and rhIL-12. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • To determine if vaccination with DC/tumor fusions and rhIL-12 results in clinically measurable disease responses. [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 41
Study Start Date: December 2009
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1
Dendritic Cell/Tumor Fusion Vaccine Only
Biological: Dendritic Cell/Tumor Fusion Vaccine
Vaccine is derived from the participants dendritic cells and tumor cells
Other Name: DC/tumor cell fusion vaccine
Experimental: Group 2
Dendritic Cell/tumor fusion vaccine and low dose IL-12
Biological: Dendritic Cell/Tumor Fusion Vaccine
Vaccine is derived from the participants dendritic cells and tumor cells
Other Name: DC/tumor cell fusion vaccine
Drug: Interleukin-12
Given subcutaneously at dose of 30ng/kg
Other Names:
  • IL-12
  • rhIL-12
Experimental: Group 3
Dendritic Cell/tumor fusion vaccine and higher dose IL-12
Biological: Dendritic Cell/Tumor Fusion Vaccine
Vaccine is derived from the participants dendritic cells and tumor cells
Other Name: DC/tumor cell fusion vaccine
Drug: Interleukin-12
Given subcutaneously at dose of 100ng/kg
Other Names:
  • IL-12
  • rhIL-12

Detailed Description:

TUMOR COLLECTION: Tumor cells will be collected from the participant to make the study vaccine. Based on the location of the tumor, a decision will be made as to the best approach to obtain these cells.

DENDRITIC CELL COLLECTION: Participants will undergo a procedure known as leukapheresis to obtain their dendritic cells (this procedure may be done before or after the tumor cells have been obtained). This procedure takes about 2-4 hours. If not enough cells are collected, the participant may be asked to return for an additional leukapheresis procedure. If sufficient number of cells are obtained, tumor cells and dendritic cells will then be fused (combined together to make one larger cell) together in the laboratory and divided into the appropriate dose for administration.

TREATMENT: Treatment will consist of an injection of tumor cells fused with dendritic cells under the skin every 3 weeks for a total of 9 weeks. The dose that the participant receives will depend on the total number of fusion cells that are made.

STUDY COHORTS: The first group of three participants will receive the DC/Tumor Fusion study vaccine alone. The next group of 3 participants will receive the DC/Tumor Fusion study vaccine with a low dose of Il-12. If there are no significant side effects the following groups of subjects will be treated with the DC/Tumor Fusion study vaccine and a higher dose of Il-12.

PATIENT MONITORING: Participants will be carefully monitored during the study period and the following tests and procedures will be performed: physical exams (weekly); blood collections (weekly); DC/Tumor Fusion study vaccine Journal (for the participant to record any side effects or other medications they may be taking); tumor cells skin test (before the first vaccine and one month following the last vaccine); skin biopsy at the site of the vaccination administration, accessible tumor site, or if there is a local reaction site.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stage IV breast cancer with measurable disease and accessible tumor
  • ECOG Performance Status 0-2 with greater than six week life expectancy
  • 18 years of age or older
  • Laboratory values as outlined in the protocol

Exclusion Criteria:

  • Patients must not have received other immunotherapy treatment in the three months prior to the initial vaccination
  • Patients may not be on herceptin therapy during this protocol and may not have received it for four weeks prior to initial vaccination
  • Patients must not have received weekly chemotherapy or hormonal treatment for two weeks prior to the initial vaccination and must not have received monthly chemotherapy for four weeks prior to the initial vaccination
  • Clinical evidence of CNS disease
  • Clinically significant autoimmune disease
  • Patients who are HIV+
  • Serious intercurrent illness such as infection requiring IV antibiotics, or significant cardiac disease characterized by significant arrhythmia, ischemic coronary disease or congestive heart failure
  • Pregnant of lactating women will be excluded, all premenopausal women must undergo pregnancy testing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00622401

Locations
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Harvard Medical School
Investigators
Principal Investigator: David Avigan, MD Beth Israel Deaconess Medical Center
  More Information

No publications provided

Responsible Party: David Avigan, MD, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT00622401     History of Changes
Obsolete Identifiers: NCT00731406
Other Study ID Numbers: 03-221, NCI 6040, U01CA062490, P30CA006516
Study First Received: February 14, 2008
Last Updated: September 15, 2014
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration
United States: Department of Defence
United States: National Cancer Institute

Keywords provided by Dana-Farber Cancer Institute:
stage IV breast cancer
dendritic cell vaccine
tumor fusion vaccine
IL-12

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Interleukin-12
Adjuvants, Immunologic
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 22, 2014